Alumis Inc. (NASDAQ:ALMS) is Towerview LLC’s 8th Largest Position

Towerview LLC boosted its stake in shares of Alumis Inc. (NASDAQ:ALMS) by 22.6% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 380,000 shares of the company’s stock after acquiring an additional 70,000 shares during the quarter. Alumis accounts for about 2.6% of Towerview LLC’s investment portfolio, making the stock its 8th largest holding. Towerview LLC owned approximately 0.80% of Alumis worth $4,058,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of the stock. Maven Securities LTD purchased a new stake in Alumis during the 2nd quarter valued at about $332,000. Millennium Management LLC purchased a new stake in Alumis in the 2nd quarter worth approximately $3,376,000. Yu Fan purchased a new stake in Alumis in the 2nd quarter worth approximately $10,502,000. Ally Bridge Group NY LLC purchased a new stake in Alumis in the 2nd quarter worth approximately $8,229,000. Finally, SR One Capital Management LP purchased a new stake in Alumis in the 2nd quarter worth approximately $26,067,000.

Wall Street Analyst Weigh In

ALMS has been the subject of several research analyst reports. Baird R W upgraded Alumis to a “strong-buy” rating in a report on Thursday, October 31st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alumis in a report on Thursday. Morgan Stanley initiated coverage on Alumis in a report on Tuesday, July 23rd. They issued an “overweight” rating and a $36.00 price objective for the company. Leerink Partnrs upgraded Alumis to a “strong-buy” rating in a report on Tuesday, July 23rd. Finally, Leerink Partners initiated coverage on Alumis in a research note on Tuesday, July 23rd. They issued an “outperform” rating and a $29.00 target price for the company. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Alumis presently has an average rating of “Buy” and an average price target of $26.83.

Alumis Stock Down 5.2 %

ALMS stock traded down $0.56 on Thursday, reaching $10.25. 33,126 shares of the company traded hands, compared to its average volume of 149,133. Alumis Inc. has a one year low of $9.54 and a one year high of $13.53. The firm’s fifty day simple moving average is $11.33.

Alumis (NASDAQ:ALMS) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($23.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.57) by ($21.53). On average, research analysts expect that Alumis Inc. will post -8 earnings per share for the current fiscal year.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.